Hence, it could be that “aberrant” MAMs in cancer cells or abnormal expression of TRIAP1/PRELI would modulate cardiolipin levels and cytochrome c release, and thus cell susceptibility to apoptosis that can be exploited for cancer therapy. This evidence concerns the gene TRIAP1 and cancer.